MEDX HEALTH CORP (MDX.CA) Fundamental Analysis & Valuation

TSX-V:MDX • CA5850901037

0.05 CAD
0 (-9.09%)
Last: Mar 9, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MDX.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

Taking everything into account, MDX scores 1 out of 10 in our fundamental rating. MDX was compared to 14 industry peers in the Health Care Equipment & Supplies industry. MDX may be in some trouble as it scores bad on both profitability and health. MDX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. MDX.CA Profitability Analysis

1.1 Basic Checks

  • In the past year MDX has reported negative net income.
  • MDX had a negative operating cash flow in the past year.
  • MDX had negative earnings in each of the past 5 years.
  • MDX had a negative operating cash flow in each of the past 5 years.
MDX.CA Yearly Net Income VS EBIT VS OCF VS FCFMDX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M -5M

1.2 Ratios

  • MDX has a worse Return On Assets (-422.39%) than 71.43% of its industry peers.
Industry RankSector Rank
ROA -422.39%
ROE N/A
ROIC N/A
ROA(3y)-597.39%
ROA(5y)-591.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MDX.CA Yearly ROA, ROE, ROICMDX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600

1.3 Margins

  • With a Gross Margin value of 33.60%, MDX is not doing good in the industry: 71.43% of the companies in the same industry are doing better.
  • MDX's Gross Margin has declined in the last couple of years.
  • MDX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 33.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.51%
GM growth 5Y-6.59%
MDX.CA Yearly Profit, Operating, Gross MarginsMDX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. MDX.CA Health Analysis

2.1 Basic Checks

  • MDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MDX has more shares outstanding
  • Compared to 5 years ago, MDX has more shares outstanding
  • The debt/assets ratio for MDX has been reduced compared to a year ago.
MDX.CA Yearly Shares OutstandingMDX.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
MDX.CA Yearly Total Debt VS Total AssetsMDX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

  • Based on the Altman-Z score of -78.68, we must say that MDX is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -78.68, MDX is not doing good in the industry: 71.43% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -78.68
ROIC/WACCN/A
WACC9.56%
MDX.CA Yearly LT Debt VS Equity VS FCFMDX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M -6M -8M

2.3 Liquidity

  • A Current Ratio of 0.10 indicates that MDX may have some problems paying its short term obligations.
  • MDX has a worse Current ratio (0.10) than 71.43% of its industry peers.
  • A Quick Ratio of 0.06 indicates that MDX may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.06, MDX is doing worse than 71.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.1
Quick Ratio 0.06
MDX.CA Yearly Current Assets VS Current LiabilitesMDX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. MDX.CA Growth Analysis

3.1 Past

  • MDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -54.10%.
  • The Revenue has grown by 42.09% in the past year. This is a very strong growth!
  • Measured over the past years, MDX shows a very negative growth in Revenue. The Revenue has been decreasing by -10.66% on average per year.
EPS 1Y (TTM)-54.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65.38%
Revenue 1Y (TTM)42.09%
Revenue growth 3Y-4.55%
Revenue growth 5Y-10.66%
Sales Q2Q%49.34%

3.2 Future

  • Based on estimates for the next years, MDX will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.33% on average per year.
  • The Revenue is expected to grow by 187.43% on average over the next years. This is a very strong growth
EPS Next Y-50.36%
EPS Next 2Y-22.62%
EPS Next 3Y19.33%
EPS Next 5YN/A
Revenue Next Year14.21%
Revenue Next 2Y170%
Revenue Next 3Y187.43%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MDX.CA Yearly Revenue VS EstimatesMDX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M 10M
MDX.CA Yearly EPS VS EstimatesMDX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2025 2026 2027 -0 -0.01 -0.01 -0.02

More info and screens

Find the best growth stocksShow best growing peers

0

4. MDX.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • MDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDX.CA Price Earnings VS Forward Price EarningsMDX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDX.CA Per share dataMDX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.01 -0.02 -0.03

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MDX's earnings are expected to grow with 19.33% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.62%
EPS Next 3Y19.33%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MDX.CA Dividend Analysis

5.1 Amount

  • MDX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MDX.CA Fundamentals: All Metrics, Ratios and Statistics

MEDX HEALTH CORP

TSX-V:MDX (3/9/2026, 7:00:00 PM)

0.05

0 (-9.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)12-01
Earnings (Next)04-27
Inst Owners0.01%
Inst Owner ChangeN/A
Ins Owners26.75%
Ins Owner ChangeN/A
Market Cap16.40M
Revenue(TTM)522.90K
Net Income(TTM)-5.30M
Analysts84.44
Price Target0.29 (480%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-37.78%
PT rev (3m)-37.78%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 31.36
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -422.39%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 33.6%
FCFM N/A
ROA(3y)-597.39%
ROA(5y)-591.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.51%
GM growth 5Y-6.59%
F-Score3
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.1
Quick Ratio 0.06
Altman-Z -78.68
F-Score3
WACC9.56%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-54.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65.38%
EPS Next Y-50.36%
EPS Next 2Y-22.62%
EPS Next 3Y19.33%
EPS Next 5YN/A
Revenue 1Y (TTM)42.09%
Revenue growth 3Y-4.55%
Revenue growth 5Y-10.66%
Sales Q2Q%49.34%
Revenue Next Year14.21%
Revenue Next 2Y170%
Revenue Next 3Y187.43%
Revenue Next 5YN/A
EBIT growth 1Y-28.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.8%
OCF growth 3YN/A
OCF growth 5YN/A

MEDX HEALTH CORP / MDX.CA FAQ

What is the fundamental rating for MDX stock?

ChartMill assigns a fundamental rating of 1 / 10 to MDX.CA.


What is the valuation status for MDX stock?

ChartMill assigns a valuation rating of 0 / 10 to MEDX HEALTH CORP (MDX.CA). This can be considered as Overvalued.


Can you provide the profitability details for MEDX HEALTH CORP?

MEDX HEALTH CORP (MDX.CA) has a profitability rating of 0 / 10.


What is the expected EPS growth for MEDX HEALTH CORP (MDX.CA) stock?

The Earnings per Share (EPS) of MEDX HEALTH CORP (MDX.CA) is expected to decline by -50.36% in the next year.